Study population and design
This retrospective, descriptive and observational registry reviewed the echocardiographic findings of patients aged 0-100 years who were presented to our outpatient cardiology clinic at a tertiary training hospital in Mogadishu, between January 1, 2019, and January 1, 2020. Overall, 6782 subjects admitted to the hospital were reviewed. 5642 individuals who had incomplete, unreliable data and/or those with completely normal echocardiographic findings were extracted from the study. Accordingly, a total of 1140 patients with pathological echocardiographic findings were enrolled in the study. Demographic characteristics and echocardiographic parameters including ejection fraction (EF), interventricular septum (IVS) thickness, left ventricular (LV) diastolic dysfunction grade, mitral valve insufficiency/stenosis, and degenerative, rheumatic, and congenital heart diseases were analyzed for each participant. Echocardiographic evaluations were performed by experienced echocardiographers who were licensed in Turkey using a Toshiba Aplio™ ultrasound system (TUS-A500, Shimoishigami, Japan) in accordance with the American Society of Echocardiography guidelines[6].Those aged 15 and under were defined as a child. Age- and gender-based distributions of acquired, congenital, and rheumatic heart diseases were evaluated. Those with active tuberculosis or a history of TB were evaluated together, regardless of whether they received treatment or not. The study was conducted according to the Helsinki Declaration. Ethical approval was obtained from the local ethics committee (date:17.02.2021,decision no:323).The need for informed consent was waived due to the retrospective nature of the study.
Hypertensive heart disease (HHD) was diagnosed in the presence of signs of heart failure or criteria for left ventricular hypertrophy (LVH) on electrocardiography (ECG) or echocardiography, considered not to be caused by valvular heart disease (VHD) and/or ischemic heart disease (IHD), for known or newly diagnosed hypertensive patients (TA > 140/90 mmHg), regardless of systolic or diastolic dysfunction.
Valvular heart disease (VHD) was defined as an obvious function and size abnormality, insufficiency/stenosis, abnormal thickening of valve leaflets or cusps, coaptation failure, calcification, and loss of normal contour detected by echocardiography in at least one of the heart valves.
Rheumatic heart disease (RHD) was diagnosed in accordance with the 2012 World Heart Federation (WHF) criteria for echocardiographic diagnosis of RHD[7].
Ischemic heart disease (IHD) was diagnosed in patients with a history of angina pectoris or a history of myocardial infarction, or an ECG feature indicating a previous myocardial infarction and a regional wall motion abnormality suggestive of myocardial infarction detected on echocardiography.
Dilated cardiomyopathy (DCM) was defined as left ventricular or biventricular systolic dysfunction and dilatation (left ventricular end-diastolic diameter > 58mm for males and > 52mm for females), not explained by abnormal filling conditions or coronary artery disease, regardless of being primary or secondary[8].
Hypertrophic cardiomyopathy (HCM) was defined as unexplained maximal wall thickness > 15 mm in any left ventricular myocardial segment or presence of left ventricular septal/posterior wall thickness ratio > 1.3 in normotensive patients and > 1.5 in hypertensive patients[9, 10].Since HCM patients in our study were adults, both thresholds were applied to all of them.
Pericardial effusion (PE) was diagnosed in the presence of an echo-freespace between the visceral and the parietalpericardium. The classification was as follows: mild(< 10mm),moderate (10-20mm), and severe (> 20mm).
Constrictive pericarditis was diagnosed in the presence of echocardiographic signs of constriction characterized by a thickened, fibrotic pericardium, limiting the heart's ability to function normally.
Heart failure with reduced EF (HFrEF) was diagnosed in the presence of clinical signs of heart failure, along with a reduced EF of <%50 assessed by echocardiography.
Pulmonary arterial hypertension was defined as the presence of systolic pulmonary artery pressure (SPAP) ≥ 2.8 m/sec or ≥ 36 mmHg on echocardiography, in addition to symptoms and other findings that are associated with pulmonary hypertension(11).